Radio
Now Playing
Quickyla Radio โ€” Click to play
Open โ†’
3 min left
Back to News

Caribou Biosciences (CRBU) Gets A Higher Target As Confidence In Its Pipeline Grows

With a stock price of $2.36, Caribou Biosciences, Inc.ย (NASDAQ: CRBU )ย is among the 8 Best Up and Coming Penny Stocks to Buy Now . Caribou Biosciences, Inc. (NASDAQ:CRBU) attracted renewed attention after H.C. Wainwright analyst Robert Burns increased his price target on the sto

Caribou Biosciences (CRBU) Gets A Higher Target As Confidence In Its Pipeline Grows
Yahoo Finance โ€” 31 May 2026
Text:
3 0 0

With a stock price of $2.36, Caribou Biosciences, Inc.ย (NASDAQ: CRBU )ย is among the 8 Best Up and Coming Penny Stocks to Buy Now .

Caribou Biosciences, Inc. (NASDAQ:CRBU) attracted renewed attention after H.C. Wainwright analyst Robert Burns increased his price target on the stock to $11 from $9 on May 11 while maintaining a Buy rating following the companyโ€™s first-quarter results. The revised target reflects growing confidence in Caribouโ€™s development pipeline and clinical progress, highlighting the potential value investors could realize if the company continues to execute on its strategic and operational objectives.

Earlier, on March 31, Caribou Biosciences, Inc. (NASDAQ:CRBU) announced that the U.S. Food and Drug Administration had granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011 for the treatment of relapsed or refractory multiple myeloma. CB-011 is an allogeneic anti-BCMA CAR-T cell therapy currently being evaluated in the ongoing Phase 1 CaMMouflage clinical trial. The RMAT designation is intended to expedite the development and review of promising regenerative medicine therapies and represents an important regulatory milestone that could help accelerate the programโ€™s path toward commercialization.

Caribou Biosciences, Inc. (NASDAQ:CRBU) is a clinical-stage biopharmaceutical company headquartered in Berkeley, California, and was founded in 2011. The company focuses on developing next-generation, off-the-shelf CRISPR-edited cell therapies for patients with cancer and autoimmune diseases. The company completed its initial public offering in 2021.

While we acknowledge the potential of CRBU as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .

READ NEXT: 10 Best Growth Stocks to Buy with Low P/E Ratios and 9 Best Space Stocks to Buy According to Reddit and Social Media .

Advertisement
React:
Sources
Sponsored

More to Read

Sam Altman says OpenAI's top token spender uses 100 billionโ€ฆ
๐Ÿ“ˆ Markets & Finance
Sam Altman says OpenAI's top token spender uses 100 billion tokens a month โ€” and they're โ€ฆ
Business Insider Mkt ยท 17 hours ago
A new NJ bill would hand pet owners up to $900 in tax crediโ€ฆ
๐Ÿ“ˆ Markets & Finance
A new NJ bill would hand pet owners up to $900 in tax credits โ€” and your state could be nโ€ฆ
Yahoo Finance ยท 2 days ago
This Smartโ€‘Money Legend Won Big on Intel. The Rest of His Pโ€ฆ
๐Ÿ“ˆ Markets & Finance
This Smartโ€‘Money Legend Won Big on Intel. The Rest of His Portfolio Might Be Even More Reโ€ฆ
Yahoo Finance ยท 2 days ago
'Astonishing': James Webb telescope spots the most chemicalโ€ฆ
๐Ÿ”ฌ Science
'Astonishing': James Webb telescope spots the most chemically primitive galaxy in the ancโ€ฆ
Live Science ยท 3 days ago
Donโ€™t underestimate young athletes โ€” the NAACP boycott planโ€ฆ
โšฝ Sports
Donโ€™t underestimate young athletes โ€” the NAACP boycott plan could actually work
Yahoo Sports ยท 2 days ago
How 'confused' AI rollout hurts firms and baffles staff
๐Ÿ’ฐ Business
How 'confused' AI rollout hurts firms and baffles staff
BBC Business ยท 2 days ago
Full view